Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
NCT ID: NCT01310686
Last Updated: 2018-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
40 participants
OBSERVATIONAL
2011-04-30
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
NCT01213667
Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients
NCT01644513
A Study of EXG102-031 in Patients With wAMD (Everest)
NCT05903794
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
NCT03699618
Genetic Load and Phenotype in Aggressive AMD
NCT01650948
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Wet AMD Non-Responders to Anti-VEGF
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had \>10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator
Exclusion Criteria
* Subjects with Serous Pigment Epithelial Detachments
* Subjects with history of the following:
idiopathic polypoidal choroidal vasculopathy
* pathologic degenerative myopia
* central serous chorioretinopathy
* familial drusen
* adult onset foveal pattern dystrophy
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
West Coast Retina Medical Group, Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arthur D. Fu, MD
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
West Coast Retina Medical Group, Inc.
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FVF4990s
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.